Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Meta Announces Its Own AI Chips. Is the Era of Full Dependence on NVIDIA Slowly Coming to an End?
Vodafone shares surge 13% after Xavier Niel's £4.4 billion investment. What's next for the stock?
🚩 Apollo Global warns on AI: Has the market become too optimistic?
Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence